[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 25, 1957


Author Affiliations

3, Litfield Pl. Bristol, 8, England.

77, Harley St. London, W. l., England.

JAMA. 1957;164(4):486. doi:10.1001/jama.1957.02980040126027

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  Orally given methyltestosterone has been used in clinical practice since its introduction by Foss in 1939 (Brit. M. J.2:11, 1939) both for its anabolic and for its androgen effects. It was not until 1947 that Werner (Am. J. Med.3:52, 1947) suggested that its use might rarely be associated with jaundice. Other reports followed (Kinsell, L. W.: Gastroenterology11:672, 1948; Werner, S. C.; Hanger, F. M.; and Kritzler, R. A.: Am. J. Med.8:325, 1950; Wood, J. C.: J. A. M. A.150:1484-1486 [Dec. 13] 1952; Van Dommelen, C. K. V., and Van der Steur, J. C.: Nederl. tijdschr. geneesk.99:2732, 1955; Brick, I. B., and Kyle, L. H.: New England J. Med.246:176, 1952). According to Werner and co-workers (ibid.) the whole picture of jaundice associated with methyltestosterone seems to be due to bile stasis. Biopsy showed dilated

First Page Preview View Large
First page PDF preview
First page PDF preview